Preparation for Akiram’s EIC Accelerator application
| Reference number | |
| Coordinator | Akiram Therapeutics AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | December 2023 - December 2024 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Preparation project for international proposal in health and food 2023 |
Important results from the project
The goal of the project was to write and submit grant applications for EIC Accelerator and for Eurostars. The project has been very successful. We were awarded Eurostars, and have qualified to, and performed, the final interviews for EIC Accelerator (decisions will be made in February). Additionally, the project contributed to strengthening Akiram’s strategic positioning and refining the clinical study plan.
Expected long term effects
The project is expected to have long-term effects by enabling a new cancer treatment, improving patient survival and quality of life. It may also strengthen Swedish research and innovation in radiopharmaceuticals, attract investments, and foster collaborations with global pharmaceutical companies. In the long run, the project could reduce healthcare costs and establish Akiram as a leading player in precision medicine.
Approach and implementation
The project "Preparation for Akiram’s EIC Accelerator application" was conducted by Akiram Therapeutics with support from UpSpark to prepare a grant application for the EIC Accelerator program. The work included developing short and full proposals, identifying clinical trial sites, and preparing for clinical studies. The focus was on developing the CD44v6 antibody for treating head and neck cancer, aiming to secure funding for clinical trials and potential out-licensing to pharma companies.